Skip to main content
Caplight Logo









Pluvia Biotech

Pluvia Biotech

Private
BergenHealthcare & Life Scienceshttps://pluviabiotech.com/

Last Round

Seed

May 19, 2026

Total Funding Raised

$1.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Pluvia Biotech is a biotechnology company that develops oral pharmacological chaperones for the treatment of rare genetic disorders caused by protein misfolding, such as phenylketonuria (PKU).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

pharmacological chaperonesphenylketonuriaPKUrare disease drugorphan drugprotein misfoldingsmall-molecule drugbiotech spin-outdrug discoverypreclinical developmentmetabolic disordertherapeutic candidaterare disease biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pluvia Biotech Comparables

Compare Pluvia Biotech with similar companies based on industry and business-model similarity.

Pluvia Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Atlas Molecular Pharma
82%
SOM Biotech
81%
Otsuka Holdings
75%

Pluvia Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 19, 2026
GrantNov 25, 2025
SeedMar 1, 2017

Key People

Founding team and executive leadership

Torgeir Vaage

Chief Financial Officer

Executive Team

Pluvia Biotech Investors

Notable investors and investment history

Pluvia Biotech investors
InvestorRounds
InvestinorSeed
Tidligfasekapital VestlandSeed
Trond Mohn Research FoundationSeed
SarsiaSeed
MABASeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 213% MoM, reaching 2.4K.

  • May 19, 2026

    Secured Seed funding from Investinor, Sarsia, and others.

Pluvia Biotech Filings

Explore SEC and related filing metadata, where available.

Pluvia Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pluvia Biotech's valuation, stock price, and market status.

Is Pluvia Biotech a public or private company?

Pluvia Biotech is a private company.

What is the current stock price of Pluvia Biotech?

Pluvia Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Pluvia Biotech worth (valuation)?

Valuation information for Pluvia Biotech is not publicly available.

Can I buy Pluvia Biotech stock?

Pluvia Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Pluvia Biotech's last funding round?

Pluvia Biotech's most recent funding round was Seed on May 19, 2026.

Who are the main investors in Pluvia Biotech?

Key investors in Pluvia Biotech include Investinor, Tidligfasekapital Vestland, Trond Mohn Research Foundation, Sarsia, MABA.

Will Pluvia Biotech IPO soon?

No public IPO plans have been announced for Pluvia Biotech.

How can I track Pluvia Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pluvia Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBergen
Employee Range10
Year Founded2015
Last FundingMay 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?